Dose escalation trial of lobaplatin combined with paclitaxel in patients with advanced non-small cell lung cancer as the first-line therapy
QIN Shukui
CHENG Ying
CHEN Zhendong
SHI Jianhua
SUN Xu
Abstract：Objective To define the maximum-tolerated dose (MTD) of lobaplatin in combination with fixed-dose paclitaxel for Chinese patients with advanced non-small cell lung cancer (NSCLC) as the first-line therapy. Methods Escalating doses of lobaplatin with fixed paclitaxel dose of 175 mg/m2 were administered. The initial dose of lobaplatin was 20 mg/m2; escalating dose was 10 mg/m2. Each group had 3 patients at least. Patients proceeded to the next group until dose-limiting toxicity (DLT) appeared. The MTD was declared to be 1 dose level below the level at which DLT appeared. Efficacy and toxicity were evaluated regularly. Results Fifteen patients were enrolled, including 3 patients in 20 mg/m2,6 patients in 30 mg/m2 and 6 patients in 40 mg/m2. Two patients occurred DLT in group of 40 mg/m2, so the MTD was 30 mg/m2. Fourteen of them were assessable. Disease control rate was 71.4％ (10/14). The most common toxicity was reversible bone marrow suppression. Conclusion The recommended dose of lobaplatin in combination with paclitaxel for patients with advanced NSCLC as the first-line therapy was 30 mg/m2. Thus the regimen is reliable, tolerable and worthy of further clinical study.
Keywords：Non-small cell lung cancerLobaplatinPaclitaxelDose escalationTolerability
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 97-100 )